{"downloaded": true, "htmlmade": false, "full": {"id": "33327268", "source": "MED", "pmid": "33327268", "pmcid": "PMC7738079", "fullTextIdList": {"fullTextId": "PMC7738079"}, "doi": "10.1097/md.0000000000023418", "title": "PERCEPTION Trial protocol: Comparison of predictive and prognostic capacities of neutrophil, lymphocyte, and platelet counts and tumor-infiltrating lymphocytes in triple negative breast cancer.", "authorString": "Lusho S, Durando X, Bidet Y, Molnar I, Kossai M, Bernadach M, Lacrampe N, Veyssiere H, Cavaille M, Gay-Bellile M, Radosevic-Robin N, Abrial C.", "authorList": {"author": [{"fullName": "Lusho S", "firstName": "Sejdi", "lastName": "Lusho", "initials": "S", "authorId": {"@type": "ORCID", "#text": "0000-0002-2359-6308"}, "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Universit\u00e9 Clermont Auvergne, INSERM UMR 1240 \u00abImagerie Mol\u00e9culaire et Strat\u00e9gies Th\u00e9ranostiques\u00bb, Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand."}, {"affiliation": "D\u00e9l\u00e9gation Recherche Clinique & Innovation, Centre Jean Perrin, 58 rue Montalembert, F-63011 Clermont-Ferrand."}, {"affiliation": "Centre d'Investigation Clinique, UMR501, F-63001 Clermont-Ferrand."}]}}, {"fullName": "Durando X", "firstName": "Xavier", "lastName": "Durando", "initials": "X", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Universit\u00e9 Clermont Auvergne, INSERM UMR 1240 \u00abImagerie Mol\u00e9culaire et Strat\u00e9gies Th\u00e9ranostiques\u00bb, Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand."}, {"affiliation": "D\u00e9l\u00e9gation Recherche Clinique & Innovation, Centre Jean Perrin, 58 rue Montalembert, F-63011 Clermont-Ferrand."}, {"affiliation": "Centre d'Investigation Clinique, UMR501, F-63001 Clermont-Ferrand."}]}}, {"fullName": "Bidet Y", "firstName": "Yannick", "lastName": "Bidet", "initials": "Y", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Universit\u00e9 Clermont Auvergne, INSERM UMR 1240 \u00abImagerie Mol\u00e9culaire et Strat\u00e9gies Th\u00e9ranostiques\u00bb, Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand."}, {"affiliation": "Centre Jean PERRIN, Laboratoire d'oncologie mol\u00e9culaire."}]}}, {"fullName": "Molnar I", "firstName": "Ioana", "lastName": "Molnar", "initials": "I", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Universit\u00e9 Clermont Auvergne, INSERM UMR 1240 \u00abImagerie Mol\u00e9culaire et Strat\u00e9gies Th\u00e9ranostiques\u00bb, Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand."}, {"affiliation": "D\u00e9l\u00e9gation Recherche Clinique & Innovation, Centre Jean Perrin, 58 rue Montalembert, F-63011 Clermont-Ferrand."}, {"affiliation": "Centre d'Investigation Clinique, UMR501, F-63001 Clermont-Ferrand."}]}}, {"fullName": "Kossai M", "firstName": "Myriam", "lastName": "Kossai", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Universit\u00e9 Clermont Auvergne, INSERM UMR 1240 \u00abImagerie Mol\u00e9culaire et Strat\u00e9gies Th\u00e9ranostiques\u00bb, Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand."}, {"affiliation": "Centre Jean Perrin, D\u00e9partement d'anatomie et de cytologie pathologiques."}]}}, {"fullName": "Bernadach M", "firstName": "Maureen", "lastName": "Bernadach", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Universit\u00e9 Clermont Auvergne, INSERM UMR 1240 \u00abImagerie Mol\u00e9culaire et Strat\u00e9gies Th\u00e9ranostiques\u00bb, Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand."}, {"affiliation": "D\u00e9l\u00e9gation Recherche Clinique & Innovation, Centre Jean Perrin, 58 rue Montalembert, F-63011 Clermont-Ferrand."}]}}, {"fullName": "Lacrampe N", "firstName": "Nathalie", "lastName": "Lacrampe", "initials": "N", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Universit\u00e9 Clermont Auvergne, INSERM UMR 1240 \u00abImagerie Mol\u00e9culaire et Strat\u00e9gies Th\u00e9ranostiques\u00bb, Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand."}, {"affiliation": "Centre Jean Perrin, D\u00e9partement d'anatomie et de cytologie pathologiques."}]}}, {"fullName": "Veyssiere H", "firstName": "Hugo", "lastName": "Veyssiere", "initials": "H", "authorId": {"@type": "ORCID", "#text": "0000-0003-2202-7362"}, "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Universit\u00e9 Clermont Auvergne, INSERM UMR 1240 \u00abImagerie Mol\u00e9culaire et Strat\u00e9gies Th\u00e9ranostiques\u00bb, Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand."}, {"affiliation": "D\u00e9l\u00e9gation Recherche Clinique & Innovation, Centre Jean Perrin, 58 rue Montalembert, F-63011 Clermont-Ferrand."}, {"affiliation": "Centre d'Investigation Clinique, UMR501, F-63001 Clermont-Ferrand."}]}}, {"fullName": "Cavaille M", "firstName": "Mathias", "lastName": "Cavaille", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Universit\u00e9 Clermont Auvergne, INSERM UMR 1240 \u00abImagerie Mol\u00e9culaire et Strat\u00e9gies Th\u00e9ranostiques\u00bb, Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand."}, {"affiliation": "Centre Jean Perrin, D\u00e9partement d'oncog\u00e9n\u00e9tique, 58 rue Montalembert, 63011 Clermont-Ferrand, France."}]}}, {"fullName": "Gay-Bellile M", "firstName": "Mathilde", "lastName": "Gay-Bellile", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Universit\u00e9 Clermont Auvergne, INSERM UMR 1240 \u00abImagerie Mol\u00e9culaire et Strat\u00e9gies Th\u00e9ranostiques\u00bb, Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand."}, {"affiliation": "Centre Jean Perrin, D\u00e9partement d'oncog\u00e9n\u00e9tique, 58 rue Montalembert, 63011 Clermont-Ferrand, France."}]}}, {"fullName": "Radosevic-Robin N", "firstName": "Nina", "lastName": "Radosevic-Robin", "initials": "N", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Universit\u00e9 Clermont Auvergne, INSERM UMR 1240 \u00abImagerie Mol\u00e9culaire et Strat\u00e9gies Th\u00e9ranostiques\u00bb, Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand."}, {"affiliation": "Centre Jean Perrin, D\u00e9partement d'anatomie et de cytologie pathologiques."}]}}, {"fullName": "Abrial C", "firstName": "Catherine", "lastName": "Abrial", "initials": "C", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Universit\u00e9 Clermont Auvergne, INSERM UMR 1240 \u00abImagerie Mol\u00e9culaire et Strat\u00e9gies Th\u00e9ranostiques\u00bb, Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand."}, {"affiliation": "D\u00e9l\u00e9gation Recherche Clinique & Innovation, Centre Jean Perrin, 58 rue Montalembert, F-63011 Clermont-Ferrand."}, {"affiliation": "Centre d'Investigation Clinique, UMR501, F-63001 Clermont-Ferrand."}]}}]}, "authorIdList": {"authorId": [{"@type": "ORCID", "#text": "0000-0002-2359-6308"}, {"@type": "ORCID", "#text": "0000-0003-2202-7362"}]}, "dataLinksTagsList": {"dataLinkstag": "supporting_data"}, "journalInfo": {"issue": "50", "volume": "99", "journalIssueId": "3068993", "dateOfPublication": "2020 Dec", "monthOfPublication": "12", "yearOfPublication": "2020", "printPublicationDate": "2020-12-01", "journal": {"title": "Medicine", "ISOAbbreviation": "Medicine (Baltimore)", "medlineAbbreviation": "Medicine (Baltimore)", "NLMid": "2985248R", "ISSN": "0304-5412", "ESSN": "1536-5964"}}, "pubYear": "2020", "pageInfo": "e23418", "abstractText": "<h4>Background</h4>Triple negative breast cancer affects 10% to 20% of all women diagnosed with breast cancer. Due to its characteristics, treatment strategies are limited and metastatic recurrences are common in the first 5 years after treatment. However, not all patients affected by this disease develop metastases. Tumor-infiltrating lymphocytes have shown to be reliable predictive biomarkers of treatment response and metastatic recurrences. However, we need to develop simpler and faster ways to predict response to cytotoxic treatment and the possibility of eventual cancer relapse by identifying new biomarkers. Recently, new studies are emerging, suggesting a predictive role of circulating blood cells in different types of cancer. In this study, we will assess the correlation between tumor-infiltrating lymphocytes and different elements of the blood count in patients diagnosed with triple negative breast cancer.<h4>Methods</h4>The main objective of this study is to evaluate the correlation between the peripheral neutrophil-to-lymphocyte ratio and the amount of tumor-infiltrating lymphocytes, assessed in triple negative breast cancer patients at diagnosis. Secondary objectives include evaluation of the correlation between tumor-infiltrating lymphocytes at diagnosis and the baseline absolute neutrophil, lymphocyte, and platelet counts, as well as the platelet-to-lymphocyte ratio. The triple negative breast cancer patients will be enrolled in the PERCEPTION trial during the first year after the treatment completion. Two supplementary blood tests, at 12 months after the end of treatment and at the time of the first metastatic recurrence, will be performed.<h4>Discussion</h4>The discovery of new prognostic and predictive biomarkers is crucial for triple negative breast cancer. We set up the PERCEPTION clinical trial in order to evaluate certain blood counts as early biomarkers and to assess their correlation with tumor-infiltrating lymphocytes. Demonstration of comparative predictive and/or prognostic capacities of peripheral blood counts and tumor-infiltrating lymphocytes would allow introduction of the former as simple and cheap biomarkers in triple negative breast cancer patient management.<h4>Trial registration</h4>The PERCEPTION study has been registered in the French National Agency of Medical Security registry on the 2nd of July 2019 under the number 2019-A01861-56 and in the ClinicalTrials.org registry under the number NCT04068623.", "affiliation": "Universit\u00e9 Clermont Auvergne, INSERM UMR 1240 \u00abImagerie Mol\u00e9culaire et Strat\u00e9gies Th\u00e9ranostiques\u00bb, Centre Jean Perrin, 58 rue Montalembert, 63000 Clermont-Ferrand.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print", "pubTypeList": {"pubType": ["Clinical Trial Protocol", "research-article", "Journal Article"]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Blood Platelets", "meshQualifierList": {"meshQualifier": {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Neutrophils", "meshQualifierList": {"meshQualifier": {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Lymphocytes", "meshQualifierList": {"meshQualifier": {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Lymphocytes, Tumor-Infiltrating", "meshQualifierList": {"meshQualifier": {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Breast Neoplasms", "meshQualifierList": {"meshQualifier": [{"abbreviation": "BL", "qualifierName": "blood", "majorTopic_YN": "Y"}, {"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Neoplasm Recurrence, Local", "meshQualifierList": {"meshQualifier": [{"abbreviation": "BL", "qualifierName": "blood", "majorTopic_YN": "N"}, {"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Lymphocyte Count"}, {"majorTopic_YN": "N", "descriptorName": "Platelet Count"}, {"majorTopic_YN": "N", "descriptorName": "Prognosis"}, {"majorTopic_YN": "N", "descriptorName": "Predictive Value of Tests"}, {"majorTopic_YN": "N", "descriptorName": "Adolescent"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Young Adult"}, {"majorTopic_YN": "N", "descriptorName": "Triple Negative Breast Neoplasms", "meshQualifierList": {"meshQualifier": [{"abbreviation": "BL", "qualifierName": "blood", "majorTopic_YN": "Y"}, {"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Biomarkers, Tumor", "meshQualifierList": {"meshQualifier": {"abbreviation": "BL", "qualifierName": "blood", "majorTopic_YN": "N"}}}]}, "chemicalList": {"chemical": {"name": "Biomarkers, Tumor", "registryNumber": "0"}}, "subsetList": {"subset": [{"code": "AIM", "name": "Core clinical journals"}, {"code": "IM", "name": "Index Medicus"}]}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1097/MD.0000000000023418"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC7738079"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC7738079?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "N", "citedByCount": "0", "hasData": "Y", "hasReferences": "N", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2021-01-04", "dateOfCreation": "2020-12-17", "firstIndexDate": "2020-12-24", "fullTextReceivedDate": "2020-12-18", "dateOfRevision": "2021-05-07", "firstPublicationDate": "2020-12-01"}, "htmllinks": "https://europepmc.org/articles/PMC7738079", "abstract": "<h4>Background</h4>Triple negative breast cancer affects 10% to 20% of all women diagnosed with breast cancer. Due to its characteristics, treatment strategies are limited and metastatic recurrences are common in the first 5 years after treatment. However, not all patients affected by this disease develop metastases. Tumor-infiltrating lymphocytes have shown to be reliable predictive biomarkers of treatment response and metastatic recurrences. However, we need to develop simpler and faster ways to predict response to cytotoxic treatment and the possibility of eventual cancer relapse by identifying new biomarkers. Recently, new studies are emerging, suggesting a predictive role of circulating blood cells in different types of cancer. In this study, we will assess the correlation between tumor-infiltrating lymphocytes and different elements of the blood count in patients diagnosed with triple negative breast cancer.<h4>Methods</h4>The main objective of this study is to evaluate the correlation between the peripheral neutrophil-to-lymphocyte ratio and the amount of tumor-infiltrating lymphocytes, assessed in triple negative breast cancer patients at diagnosis. Secondary objectives include evaluation of the correlation between tumor-infiltrating lymphocytes at diagnosis and the baseline absolute neutrophil, lymphocyte, and platelet counts, as well as the platelet-to-lymphocyte ratio. The triple negative breast cancer patients will be enrolled in the PERCEPTION trial during the first year after the treatment completion. Two supplementary blood tests, at 12 months after the end of treatment and at the time of the first metastatic recurrence, will be performed.<h4>Discussion</h4>The discovery of new prognostic and predictive biomarkers is crucial for triple negative breast cancer. We set up the PERCEPTION clinical trial in order to evaluate certain blood counts as early biomarkers and to assess their correlation with tumor-infiltrating lymphocytes. Demonstration of comparative predictive and/or prognostic capacities of peripheral blood counts and tumor-infiltrating lymphocytes would allow introduction of the former as simple and cheap biomarkers in triple negative breast cancer patient management.<h4>Trial registration</h4>The PERCEPTION study has been registered in the French National Agency of Medical Security registry on the 2nd of July 2019 under the number 2019-A01861-56 and in the ClinicalTrials.org registry under the number NCT04068623.", "pdflinks": "https://europepmc.org/articles/PMC7738079?pdf=render", "journaltitle": "Medicine", "authorinfo": ["Lusho S", "Durando X", "Bidet Y", "Molnar I", "Kossai M", "Bernadach M", "Lacrampe N", "Veyssiere H", "Cavaille M", "Gay-Bellile M", "Radosevic-Robin N", "Abrial C"], "title": "PERCEPTION Trial protocol: Comparison of predictive and prognostic capacities of neutrophil, lymphocyte, and platelet counts and tumor-infiltrating lymphocytes in triple negative breast cancer."}